Strong Q1 masked by temporary Xanthine uplift; API pressure real

Delivered ₹535.8 Cr at 38.7% YoY (delivered result), not 42%

Delivered OPM 25.4% implies ~₹136 Cr EBITDA; math checks (133/95 = 40%)

Delivered PAT ₹76.1 Cr (14.2% NPM on ₹535.8 Cr); likely includes Ganesh Polychem consolidation

₹305 Cr (57% of 535.8) with 25% volume growth YoY; price-driven, not just volume

Q1 delivered 25.4%, elevated due to Xanthine pricing peak and lower raw material costs; not sustainable

Completed steroid block debottlenecking (+33% capacity). Brownfield Xanthine expansion (L99) commercialized, ramp in coming quarters. Second-largest global capacity target by FY28.

Block 1 (₹450 Cr, 440 kL) completing Q2. Block 2 announced (₹149 Cr, 400+ kL), groundbreaking Q3. Dedicated to CDMO; more capital-efficient than multipurpose.

Peaked May–June (+50–100% above pre-war); now 25–50% above pre-war. Management estimates 50% structural (China anti-involution duty rebate removal), 50% temporary (raw materials). Realizations declining Q2 onward.

Stuck at ₹160–165 Cr range. Pricing pressure persistent on generics. Target ₹1,000 Cr long-term, but launches delayed; anticancer expansion underway.

Q1 contribution only 7% (₹37 Cr) vs expected double-digit. Guidance 40–50% growth maintained, but lumpiness & project timing cited. Q3–Q4 expected to deliver bulk of revenue.

79% export, 21% domestic. Targeting 20–25% global share within 2 years (currently second-largest capacity).

China dominant; 80–90% of global competition still in China. India + Europe are small players.

Refuse to guide on percentage due to raw material pass-through. Company-level 20–25%. No segment-level margin guidance.

25% volume growth YoY; exact value %, need to follow up.

Realization per kg will decline, but overall sales to grow with additional capacity.

Already started for Atali Phase 1. Phase 2 (smaller) completes this quarter. All expenses hit second half.

Atali contributing now toward capacity utilization; Q3 onward partial top-line contribution after commercial ramp.

Will ramp quickly to 50% capacity; cost easily covered. No significant P&L hit.

Prices lower from peak but still elevated vs pre-war.

EBITDA margin 20–25%. Gross margin ~50% company level.

Fully utilizing additional 33% capacity going forward (1.5-month break this quarter now over).

Mitigated by increased quantities from new capacity. Absolute gross margin will sustain.

Yes; structurally increased Xanthine prices because China players can't get rebate. Helped margins in spot market.

Pricing pressure persists. Debottlenecking normalizes current quarter. New launches upcoming. Expect recovery but timing uncertain.

Yes, this year will be H2 heavy.

We deduct dropped projects. Commercial projects grew 21→37 over 3 years. 40–50% growth confident.

Strong quarter, good growth, PAT ₹7 Cr (after rationalizing ₹2.5 Cr dividend).

Guiding 22–25%. Depends on capacity operationalization. CDMO high-margin contribution will average out.

Internal target to meet ₹780 Cr, but looking at environment and launches, will not cross but nearly there.

Range ₹900–₹1,100 Cr FY27; exact level depends on price normalization path.

Asset turnover ~1x. Dedicated facility starts end of next FY, meaningful utilization 1–1.5 years post that.

10x growth in 5.5 years. Moved from ISO→GMP→now clinical batches & tox studies. 60–65% gross margin commercial, higher on early-stage.

EBITDA >30% possible at optimal utilization. 60–65% commercial CDMO gross margin is healthy. Moving to peptides/oligonucleotides could go higher.

Built CXO model: CSO, CTO, COO. 250+ scientists across 3 R&D centers (Nerul, Dombivali, Vapi). Geographically distributed BD (Europe, US, Japan leads).

Involution duty permanent structural for near-term. Raw material increase temporary (West Asia crisis). Quota tightening structural benefit.

Q1 exceptional due to crisis pricing (50–100% raw material increase, now 25–50% above pre-war). Broad range ₹900–₹1,000 Cr.

3–4 projects, multiple customers, some flexibility due to lumpy take patterns. Good visibility on combined requirements.

Atali: no mandatory USFDA requirement; customer-audited and approved. Xanthine: for food, no USFDA needed.

Current expansion sufficient for next few years. May pursue cost-saving projects with lower payback. Focus now on CDMO.

No more capex needed for ₹1,000 Cr+ API. Current debottlenecking (steroid), ongoing (anticancer), and Block 5 sufficient. Should be ₹170–190 Cr range going forward.

Q1 ₹305 Cr at peak prices. Post-normalization, guidance wide to reflect 50–50 temporary/structural price split.

Q1 miss (₹37 Cr) blamed on accounting standard and non-deliveries. H2-heavy expected to deliver growth.

Currently ₹160–165 Cr range. Launches delayed, pricing pressure persistent. Recovery to ₹1,000 Cr 'a couple of years away' per mgmt.

Q1 came at 24.9% due to temporary Xanthine/raw material benefits. Normalization expected.

Q1 at 56%. Dependent on segment mix and Xanthine price normalization.

Early-stage CDMO higher, but limited. Long-term peptide/oligonucleotide could reach 70–75%, but timeline unclear.

400+ kL capacity dedicated to CDMO. Additional 200 kL flexibility possible; civil ready, equipment scalable.

Will be second-largest global capacity post-expansion; sufficient for next few years.

Prices peaked May–June 2026 (+50–100% above pre-war); already declining June–July to +25–50% above pre-war. Management estimates 50% structural (China rebate removal), 50% temporary. Downside if prices fully revert to pre-war levels.

Stuck at ₹160–165 Cr for multiple quarters. Pricing pressure on existing molecules persists. Management targeting ₹1,000 Cr long-term, but implied CAGR unrealistic given current base. New launches (anticancer, antidiabetic) will take years to scale.

Atali Block 2 (₹149 Cr, 12–15 month timeline) announced. CDMO contribution only 7% of Q1 revenue vs double-digit expectations. Q1 miss blamed on 'accounting standard' and 'non-deliveries.' Risk of further delays if commercial shipments slip.

Multiple capacity additions across Xanthine (L99), steroid block (Unit 4), and Atali (Blocks 1 & 2). Utilization target 80%+ by FY28. If demand doesn't materialize or ramp is slower, asset turnover target (~1x) at risk.

Dedicated Atali Block 2 (₹149 Cr) designed for 3–4 projects. If any of these projects face clinical trial delays, commercial failure, or customer substitution, ROI at risk.

80–90% of global Xanthine capacity in China. Anti-involution duty removes rebate competitiveness for Chinese players, but if China quotas ease or new capacity added, pricing could revert.